We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

19 hedge funds and large institutions have $6.75M invested in Gyre Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $5.86M → $6.75M (+$889K)

0.19% more ownership

Funds ownership: 3.94% → 4.13% (+0.19%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

17% less funds holding

Funds holding: 23 → 19 (-4)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
19
Holders Change
-4
Holders Change %
-17.39%
% of All Funds
0.47%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
3
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$374K
2
SCM
Sio Capital Management
New York
+$274K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$54.6K
4
FPF
FNY Partners Fund
New York
+$18.7K
5
FMA
FNY Managed Accounts
New York
+$1.59K

Top Sellers

1
ZIM
Zacks Investment Management
Illinois
-$147K
2
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$67K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$57K
4
TSS
Two Sigma Securities
New York
-$55K
5
Renaissance Technologies
Renaissance Technologies
New York
-$23.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sio Capital Management
New York
$2.13M +$274K +9,128 +19%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.69M -$23.6K -787 -2%
BlackRock
3
BlackRock
New York
$877K – – –
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$873K +$374K +12,479 +117%
EWM
5
Essex Woodlands Management
Texas
$404K – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$289K +$54.6K +1,820 +31%
NMC
7
NEA Management Company
Maryland
$220K – – –
UBS Group
8
UBS Group
Switzerland
$123K -$7.28K -243 -7%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$111K -$3.3K -110 -4%
FPF
10
FNY Partners Fund
New York
$23K +$18.7K +623 New
FMA
11
FNY Managed Accounts
New York
$2K +$1.59K +53 New
Deutsche Bank
12
Deutsche Bank
Germany
$1K -$13K -433 -90%
Morgan Stanley
13
Morgan Stanley
New York
$1K +$989 +33 New
ZIM
14
Zacks Investment Management
Illinois
– -$147K -4,209 Closed
Tudor Investment Corp
15
Tudor Investment Corp
Connecticut
– -$67K -1,932 Closed
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$57K -1,658 Closed
TSS
17
Two Sigma Securities
New York
– -$55K -1,586 Closed
CG
18
Cutler Group
California
– -$4K -120 Closed
Group One Trading
19
Group One Trading
Illinois
– -$2K -61 Closed

GYRE Hedge Fund Activity: Q3 2017 in Review

19 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2017, worth a combined $6.75M — up 15% from $5.86M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of GYRE and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Dimensional Fund Advisors, adding an estimated $374K. The largest seller was Zacks Investment Management, exiting entirely with an estimated $147K sold.

  • 19 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2017, down from 23 in Q2 2017.
  • Funds reported $6.75M of Gyre Therapeutics stock for Q3 2017, up 15% quarter-over-quarter.
  • 3 funds opened new Gyre Therapeutics positions in Q3 2017 and 6 closed out, a net change of -3 holders.
  • The largest Gyre Therapeutics buyer in Q3 2017 was Dimensional Fund Advisors, an estimated $374K added.
  • The largest Gyre Therapeutics seller in Q3 2017 was Zacks Investment Management, an estimated $147K sold.

Based on aggregated 13F filings for Q3 2017.